摘要
目的:观察培美曲塞(PMD)与吉西他滨(GEM)分别联合顺铂辅助治疗肺腺癌术后的疗效及毒副反应。方法:回顾性分析符合条件的115例肺腺癌术后患者,其中PP(PMD联合顺铂)组56例和GP(GEM联合顺铂)组59例,每例均完成4个周期辅助化疗,观察术后复发率及化疗毒副反应。结果:PP组疾病控制率94.6%,GP组疾病控制率91.5%,两组相比较术后复发率无统计学意义(P>0.05)。化疗毒副反应主要是骨髓抑制、胃肠反应、脱发、皮肤瘙痒等。PP组化疗毒副反应显著低于GP组,有统计学意义(P<0.05)。结论:PMD联合顺铂与GEM联合顺铂辅助治疗肺腺癌术后,两者治疗效果无明显差异,但PMD联合顺铂化疗毒副反应明显较轻,可作为肺腺癌术后辅助化疗的优先推荐用药。
Objective :To observe the curative effects and sid- effects of the adjuvant treatment to postoperative patients with lung adenocarcinoma after given pemetrexed(PMD) and gemcitabine (GEM) respectively with cisplatin. Methods:Retrospectively analyze 115 eligible postoperative patients with lung adenocarcinoma ,56 of PP group and 59 of GP group, accomplished 4 -periodic adjuvant chemotherapy and observe their recurrence rate and side - effects. Results: There was no statistical significance ( P 〉 0.05 ) of the recurrence rate between PP group with the disease control rate of 94.6% and GP group 91.5%. The main side - effects of chemotherapy were myelosuppression,gastro- intestinal reaction, aopecia, cutaneous pruritus. The side - effects of PP group were dramaticlly fewer than those of GP group(P 〈 0.05). Conclusion: There was no obvious difference of cure postoperative patients with either PEM with cisplatin or GEM with cisplatin, however, GEM with cisplatinhas has fewer side - effects significantly. PEM can be preferentially recommended as an adjuvant chemotherapy of postoperative patients with lung adenocarcinoma.
出处
《现代肿瘤医学》
CAS
2014年第4期837-839,共3页
Journal of Modern Oncology
关键词
培美曲塞
吉西他滨
肺腺癌术后
化疗
pemetrexed
gemcitabine
lung adenocarcinoma
chemotherapy